1-7 of 7
Ravindra Majeti
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy

Miles H. Linde, Amy C. Fan, Thomas Köhnke, Aaron C. Trotman-Grant, Sarah F. Gurev, Paul Phan, Feifei Zhao, Naomi L. Haddock, Kevin A. Nuno, Eric J. Gars, Melissa Stafford, Payton L. Marshall, Christopher G. Dove, Ian L. Linde, Niklas Landberg, Lindsay P. Miller, Robbie G. Majzner, Tian Yi Zhang, Ravindra Majeti
Journal: Cancer Discovery
Cancer Discov (2023) 13 (5): 1164–1185.
https://doi.org/10.1158/2159-8290.CD-21-0502
Published: 04 May 2023
View articletitled, Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
Open the PDF for Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability

Daniel Thomas, Manhong Wu, Yusuke Nakauchi, Ming Zheng, Chloe A.L. Thompson-Peach, Kelly Lim, Niklas Landberg, Thomas Köhnke, Nirmal Robinson, Satinder Kaur, Monika Kutyna, Melissa Stafford, Devendra Hiwase, Andreas Reinisch, Gary Peltz, Ravindra Majeti
Journal: Cancer Discovery
Cancer Discov (2023) 13 (2): 496–515.
https://doi.org/10.1158/2159-8290.CD-21-0218
Published: 06 February 2023
View articletitled, Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability
Open the PDF for Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability in another window
Includes: Supplementary data
Journal Articles

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

Naval G. Daver, Abhishek Maiti, Tapan M. Kadia, Paresh Vyas, Ravindra Majeti, Andrew H. Wei, Guillermo Garcia-Manero, Charles Craddock, David A. Sallman, Hagop M. Kantarjian
Journal: Cancer Discovery
Cancer Discov (2022) 12 (11): 2516–2529.
https://doi.org/10.1158/2159-8290.CD-22-0332
Published: 02 November 2022
View articletitled, TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Open the PDF for TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions in another window
Journal Articles

Clonal Hematopoiesis: From Mechanisms to Clinical Intervention

Thomas Köhnke, Ravindra Majeti
Journal: Cancer Discovery
Cancer Discov (2021) 11 (12): 2987–2997.
https://doi.org/10.1158/2159-8290.CD-21-0901
Published: 02 December 2021
View articletitled, Clonal Hematopoiesis: From Mechanisms to Clinical Intervention
Open the PDF for Clonal Hematopoiesis: From Mechanisms to Clinical Intervention in another window
Journal Articles

Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist

Michael R. McKeown, M. Ryan Corces, Matthew L. Eaton, Chris Fiore, Emily Lee, Jeremy T. Lopez, Mei Wei Chen, Darren Smith, Steven M. Chan, Julie L. Koenig, Kathryn Austgen, Matthew G. Guenther, David A. Orlando, Jakob Lovén, Christian C. Fritz, Ravindra Majeti
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2017) 7 (10): 1136–1153.
https://doi.org/10.1158/2159-8290.CD-17-0399
Published: 02 October 2017
View articletitled, Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
Open the PDF for Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist in another window
Includes: Supplementary data
Journal Articles

Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models

Daniel Thomas, Ravindra Majeti
Journal: Cancer Discovery
Cancer Discov (2017) 7 (5): 459–461.
https://doi.org/10.1158/2159-8290.CD-17-0270
Published: 30 April 2017
View articletitled, Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models
Open the PDF for Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models in another window
Journal Articles

ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia

Li Zhu, Qin Li, Stephen H.K. Wong, Min Huang, Brianna J. Klein, Jinfeng Shen, Larissa Ikenouye, Masayuki Onishi, Dominik Schneidawind, Corina Buechele, Loren Hansen, Jesús Duque-Afonso, Fangfang Zhu, Gloria Mas Martin, Or Gozani, Ravindra Majeti, Tatiana G. Kutateladze, Michael L. Cleary
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2016) 6 (7): 770–783.
https://doi.org/10.1158/2159-8290.CD-16-0058
Published: 30 June 2016
View articletitled, ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia
Open the PDF for ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia in another window
Includes: Supplementary data